TrialNature communications2026

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.

Angela Damato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.